Navigation Links
Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
Date:11/3/2009

ith Clostridium difficile infection (CDI) were presented at the 47th Annual Meeting of the Infectious Diseases Society of America in October 2009. Clinical investigator Mark Miller, M.D., presented data showing that patients treated with fidaxomicin had a faster time to resolution of diarrhea compared to those treated with vancomycin. Faster time to resolution of diarrhea may reduce the spread of CDI in healthcare facilities and improve patients' quality of life. Clinical investigator Kate Mullane, D.O., presented data showing that treatment with fidaxomicin compared to vancomycin in patients also receiving concomitant antibiotics resulted in higher clinical cure rates, lower recurrence rates and improved global cure rates.
  • Seven fidaxomicin-related abstracts from Optimer's North American Phase 3 study were presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in September 2009. The additional data presented highlight fidaxomicin's unique profile as a new antibiotic class with beneficial characteristics for treating CDI such as lower recurrence rates, reduced risk of vancomycin-resistant enteroccoci (VRE) acquisition, favorable pharmacokinetic profile, and a safety profile comparable to that of vancomycin.
  • The full data analysis from the second Phase 3 clinical study for Pruvel was presented at ICAAC in September 2009. Data presented by primary investigator Robert Steffen, M.D., showed that Pruvel shortened recovery time in adult travelers suffering from infectious diarrhea.
  • The United States Patent and Trademark Office recently issued a patent which covers the composition of matter of CEM-101/(OP-1068). CEM-101/(OP-1068) is a macrolide derivative originally developed by Optimer and licensed to Cempra Pharmaceuticals who recently completed a Phase 1 clinical trial for the treatment of respiratory infections.
  • About Optimer Pharmaceuticals

    Optimer Phar
    '/>"/>

    SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
    2. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
    3. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
    4. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
    5. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
    6. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
    7. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
    8. ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results
    9. Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update
    10. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
    11. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results on November 5, 2009
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/25/2014)... October 25, 2014 The report ... & by Geography - Global Trends & Forecast ... with respect to market drivers, opportunities, and trends ... tables and 27 figures spread through 217 slides ... Global Trends & Forecast to 2019”., http://www.marketsandmarkets.com/Market-Reports/adipic-acid-269.html ...
    (Date:10/25/2014)... (PRWEB) October 23, 2014 ... specialty pharmaceutical company devoted to bringing new products ... in 2015. , ViaDerma has developed an innovative, ... for rapid mass transfer of pharmaceutical active ingredients ... to provide immediate localized therapy. The transdermal delivery ...
    (Date:10/25/2014)... (PRWEB) October 23, 2014 BioProcess ... winners for the 2014 BioProcess International Awards. The ... social corporate responsibility and technology applications that will ... treatments to a global patient base. , Winners ... peers during a very entertaining and exciting awards ...
    (Date:10/25/2014)... 2014 According to new market ... Center Types (Colocation, Enterprise, Telecom), by Design Types ... Tier 2, Tier 3, Tier 4) - Global ... segments the Data Center Construction Market into various ... revenues. This research report also identifies the factors ...
    Breaking Biology Technology:Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 2Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 3Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 4ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3BioProcess International Announces Winners of the 2014 BioProcess International Awards 2BioProcess International Announces Winners of the 2014 BioProcess International Awards 3BioProcess International Announces Winners of the 2014 BioProcess International Awards 4BioProcess International Announces Winners of the 2014 BioProcess International Awards 5Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 2Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 4
    ... “What part of ... Barry Friedberg, MD. “Is the ASA not as smart as a fifth grader?” , ... (PRWEB) March 9, 2010 -- One ... relentless pursuit of patient safety ., , , , ,Yet no answer has been forthcoming ...
    ... ... ... ... ...
    ... ... Data-mining Platform Integrates a Variety of Data Streams into One Easy-to-use Analysis System ... (PRWEB) March 8, ... life science research, today announced Genedata Analyst™, an integrated statistical and data analysis platform ...
    Cached Biology Technology:American Society of Anesthesiologists: Is Apathy or Avarice Precluding Advocacy of Better Patient Safety? 2American Society of Anesthesiologists: Is Apathy or Avarice Precluding Advocacy of Better Patient Safety? 3Atherotech's Advanced Lipid Profile Featured in Lipoprotein and Epidemiology Research at ACC 2010 2Atherotech's Advanced Lipid Profile Featured in Lipoprotein and Epidemiology Research at ACC 2010 3Atherotech's Advanced Lipid Profile Featured in Lipoprotein and Epidemiology Research at ACC 2010 4Atherotech's Advanced Lipid Profile Featured in Lipoprotein and Epidemiology Research at ACC 2010 5Atherotech's Advanced Lipid Profile Featured in Lipoprotein and Epidemiology Research at ACC 2010 6Bringing Statistics to Biologists - New Genedata Analyst Launches at Society of Toxicology 49th Annual Meeting 2Bringing Statistics to Biologists - New Genedata Analyst Launches at Society of Toxicology 49th Annual Meeting 3Bringing Statistics to Biologists - New Genedata Analyst Launches at Society of Toxicology 49th Annual Meeting 4Bringing Statistics to Biologists - New Genedata Analyst Launches at Society of Toxicology 49th Annual Meeting 5
    (Date:10/25/2014)... , Oct.  22, 2014   MedNet Solutions ... clinical study management systems, is pleased to announce the ... two-day event – to be held in ... on track to have record attendance and promises to ... The focus of the meeting is ...
    (Date:10/25/2014)... , Oct. 22, 2014 This report covers ... relatively new space in heavy pursuit of research due ... to miRNAs compared to other RNA components. miRNA,s non-coding ... a novel candidate for use as a biomarker for ... miRNA-based microarrays and diagnostics for the advancement in therapeutic ...
    (Date:10/25/2014)... Oct. 22, 2014 A recent report, "Genetic ... the current and future genetic testing market. A comprehensive ... are covered in this report. On account of our ... and existing strengths and challenges; forecast for genetic testing ... likely to grow at a CAGR of around 9% ...
    Breaking Biology News(10 mins):MedNet Solutions To Host Third Annual iMedNet User Group Meeting 2MicroRNA: An Insight to miRNA-based microarrays, diagnostics and therapeutics Overview, Cambridge Healthtech Advisors 2Genetic Testing Market Outlook 2018 2
    ... in the Sumatran jungle have captured first-time images of a ... into the elusive tiger,s behaviour. After a month in ... to record tigers in the Sumatran jungle caught the mother ... sniff and check out the camera trap. There are ...
    ... The volcanic eruptions thought responsible for Earth,s largest mass extinction ... animals 250 million years ago is still taking lives ... the first time, that the high silica content of coal ... substances in the coal to cause unusually high rates of ...
    ... A canine chromosome 7 locus that confers a high ... a collaboration between the Behavior Service at the Cummings ... at the University of Massachusetts Medical School and the ... findings are published in the January 2010 edition of ...
    Cached Biology News:Camera traps yield first-time film of tigress and cubs 2Camera traps yield first-time film of tigress and cubs 3Canine compulsive disorder gene identified in dogs 2Canine compulsive disorder gene identified in dogs 3
    Rat CINC-2 alpha/beta Affinity Purified Polyclonal Ab...
    Tachykinin (H-2)...
    ...
    ... developed to significantly increase the shelf life ... is increased at room temperature storage conditions ... product is subjected to 0.45 micron filtration, ... This formulation insures consistently high levels of ...
    Biology Products: